GentiBio builds cell therapy platforms ready for commercial scale from day one
GentiBio has developed a single, modular engineered Treg platform that supports both autologous and allogeneic products. The process uses abundant starting cells and simple, sort free unit operations that are easy to transfer and scale. Bioreactor expansion and standardized cryopreservation deliver consistent, high purity product that is ready for global deployment.
Autologous Cell Therapy
KEY CHALLENGE: Conventional autologous regulatory T cell manufacturing is slow, complex, and expensive. Multiple cell sorting steps, rare starting populations, and long culture times drive high variability and limit reliability.
OUR SOLUTION: The GentiBio platform delivers autologous products with more than 109 cells at greater than 90% purity in two weeks, without costly and complex cell sorting or reliance on rare cell types.
Allogenic Cell Therapy
KEY CHALLENGE: Typical regulatory T cell processes rely on rare starting populations, which limits batch size and makes true commercial scale difficult.
OUR SOLUTION: The GentiBio platform can generate allogeneic products with thousands of doses per batch at commercial scale, with cost of goods sold (COGS) in the low thousands per dose.